Adjunctive Coriolus versicolor may leads to higher survival ‐ compared with no adjunctive treatment (low certainty).
It is very uncertain whether adjunctive Coriolus versicolor changes withdrawal from treatment due to adverse events ‐ compared with no adjunctive treatment (very low certainty).
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Oral cavity disorders (includes oral dryness and… compared with no adjunctive treatment (very low certainty).
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Nausea ‐ compared with no adjunctive treatment (very low certainty).
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Diarrhoea ‐ compared with no adjunctive treatment (very low certainty).
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Neutrophils decreased ‐ compared with no adjunctive treatment (very low certainty).
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Fatigue ‐ compared with no adjunctive treatment (very low certainty).
Summary of Findings Table ‐ PBI?APBI probably leads to higher local recurrence‐free survival ‐ total (LR‐FS) compared with WBRT (moderate certainty).
Summary of Findings Table ‐ PBI?APBI probably leads to higher cosmesis, physician/nurse‐reported compared with WBRT (moderate certainty).
Summary of Findings Table ‐ PBI?APBI showed no clear difference in overall survival compared with WBRT (high certainty).
Summary of Findings Table ‐ PBI?APBI probably leads to higher subcutaneous fibrosis (late RT toxicity) compared with WBRT (moderate certainty).
Summary of Findings Table ‐ PBI?APBI showed no clear difference in cause‐specific survival (C‐SS) compared with WBRT (moderate certainty).
Summary of Findings Table ‐ PBI?APBI showed no clear difference in distant metastasis‐free survival (DM‐FS) compared with WBRT (moderate certainty).
Summary of Findings Table ‐ PBI?APBI showed no clear difference in subsequent mastectomy compared with WBRT (high certainty).
TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).
TACE followed by 3‐DCRT may leads to lower proportion of participants without tumour response (CR+PR) compared with TACE (low certainty).
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).